Paper Review Records
All Paper Review Records
12 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Pharmacological enhancement of O-GlcNAcylation attenuates lung ischemia-reperfusion injury
Yang Jin; Yu Fu; Nan Zhang; Xuemei Jiang; Jiameng Gao; Zhiyuan Zhang; Xiaotong Huang; Maojun Zhou; Chang Chen; Zongmei WenShow moreShow less
Department of Anesthesiology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China; Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, ChinaShow moreShow less
Belumosudil improves experimental pulmonary fibrosis via the ROCK2/Smad3/CTGF pathway
Dexin Kong; Guanghua Zhang; Zhonghong Jiang; Wanglin JiangShow moreShow less
School of Pharmacy, Shandong Medical and Pharmaceutical University, Yantai, 264003, PR China; Yantai Center for Food and Drug Control, Yantai, 264011, PR China; West China School of Pharmacy, Sichuan University, Chengdu, 640041, PR ChinaShow moreShow less
Efficacy and safety of magnesium glycinate as add on therapy in hypomagnesemic asthma and chronic obstructive pulmonary disease patients: A randomised controlled study assessing inflammatory biomarkers
Maneesh Kumar Maddirevula; Muhasaparur G. Rajanandh; Boman WesleyShow moreShow less
Department of Pharmacy Practice, SRM College of Pharmacy, Faculty of Medicine and Health Sciences, SRM Institute of Science and Technology, Kattankulathur, Chengalapattu, Tamil Nadu, 603203, India; Department of Pharmacy Practice, Mahathi College of Pharmacy, Madanapalle, Andhra Pradesh, 517319, India; Department of Pulmonary Medicine, Arogyavarm Medical Center, Madanapalle, Andhra Pradesh, 517319, IndiaShow moreShow less
m6A reader IGF2BP2 mediates airway remodeling by stabilizing Dixdc1 in asthma pathogenesis
Xiao-Mang Li; Bi-Wen Mo; Yan Gao; Yun-Xiang Chen; Bo Xiao; Yue Gu; Miao-Miao Liang; Hui-Min LiShow moreShow less
Guilin Medical University, Guilin, 541004, Guangxi, China; Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guilin Medical University, Guilin, 541001, Guangxi, China; Respiratory Disease Laboratory, The First Affiliated Hospital of Guilin Medical University, Guilin, 541004, Guangxi, ChinaShow moreShow less
Real-life application of the optical beta-adrenergic sweat test for people with cystic fibrosis
Karina Kleinfelder; Anca Manuela Hristodor; Giorgio Centin; Antonella Casiraghi; Paola Minghetti; Emily Pintani; Marina Bertini; Claudio Sorio; Paola MelottiShow moreShow less
Department of Medicine, Division of General Pathology, Cystic Fibrosis Laboratory “D. Lissandrini”, University of Verona, Verona, 37134, Italy; Cystic Fibrosis Centre, Azienda Ospedaliera Universitaria Integrata Verona, Verona, 37126, Italy; Department of Pharmaceutical Sciences, Università degli Studi di Milano, via G. Colombo 71, Milan, 20133, ItalyShow moreShow less
Effects of anumigilimab, an anti–G-CSF receptor mAb, after segmental LPS challenge: A Phase 1b trial in healthy volunteers
Jens M. Hohlfeld; Meike Müller; Philipp Badorrek; Laurent B. Nicolas; Oliver Vit; William G. Darby; Judith Field; Michael LarbigShow moreShow less
Division of Airway Research, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Nikolai-Fuchs-Str. 1, Hannover, 30625, Germany; Department of Respiratory Medicine and Infectious Disease, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover, 30625, Germany; Member of the German Center for Lung Research (DZL), BREATH, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover, 30625, Germany; Clinical Pharmacology and Pharmacometrics, CSL Behring AG, Wankdorfstrasse 10, Bern, 3014, Switzerland; Clinical Development, CSL Behring AG, Wankdorfstrasse 10, Bern, 3014, Switzerland; CSL Innovation, 30 Flemington, Parkville, 3010, AustraliaShow moreShow less
FAQ
How long does PULMONARY PHARMACOLOGY & THERAPEUTICS take to review a manuscript?
As of 2026-11-19, CrushSCI has 12 complete review records for PULMONARY PHARMACOLOGY & THERAPEUTICS. The fastest paper went from submission to acceptance in 47 days (Effects of anumigilimab, an anti–G-CSF receptor mAb, after segmental LPS challenge: A Phase 1b trial in healthy volunteers, received 2026-05-19, accepted 2026-07-05); the slowest took 351 days. The average is 160.5 days and the median is 124 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
